Objective: We report the results of pharmacogenomics-based antidepressant treatment (PGXt) results in treating treatment- resistant major depressive disorder (TRD) patients in real practice. Methods: Nine patients were prescribed Neuropharmagen? for selection of antidepressants for individual patient and their clinical outcomes were followed. Results: After treatment by PGXt results from current antidepressants, substantial reduction of depressive symptoms was observed at some point and maintained during observation period in six patients. Conclusion: Our case series potentially shows the clinical utility and benefit of PGXt for treatment of TRD patients.

Lee K.H., Bahk W.-M., Lee S.-J., Serretti A., Pae C.-U. (2021). A practical utility and benefit of pharmacogenetic-based antidepressant treatment strategy for major depressive disorder patients with difficult-to-treat. CLINICAL PSYCHOPHARMACOLOGY AND NEUROSCIENCE, 19(1), 160-165 [10.9758/CPN.2021.19.1.160].

A practical utility and benefit of pharmacogenetic-based antidepressant treatment strategy for major depressive disorder patients with difficult-to-treat

Serretti A.;
2021

Abstract

Objective: We report the results of pharmacogenomics-based antidepressant treatment (PGXt) results in treating treatment- resistant major depressive disorder (TRD) patients in real practice. Methods: Nine patients were prescribed Neuropharmagen? for selection of antidepressants for individual patient and their clinical outcomes were followed. Results: After treatment by PGXt results from current antidepressants, substantial reduction of depressive symptoms was observed at some point and maintained during observation period in six patients. Conclusion: Our case series potentially shows the clinical utility and benefit of PGXt for treatment of TRD patients.
2021
Lee K.H., Bahk W.-M., Lee S.-J., Serretti A., Pae C.-U. (2021). A practical utility and benefit of pharmacogenetic-based antidepressant treatment strategy for major depressive disorder patients with difficult-to-treat. CLINICAL PSYCHOPHARMACOLOGY AND NEUROSCIENCE, 19(1), 160-165 [10.9758/CPN.2021.19.1.160].
Lee K.H.; Bahk W.-M.; Lee S.-J.; Serretti A.; Pae C.-U.
File in questo prodotto:
File Dimensione Formato  
cpn019-01-17.pdf

accesso aperto

Tipo: Versione (PDF) editoriale
Licenza: Licenza per Accesso Aperto. Creative Commons Attribuzione - Non commerciale (CCBYNC)
Dimensione 235.13 kB
Formato Adobe PDF
235.13 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/851059
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 2
  • ???jsp.display-item.citation.isi??? 2
social impact